Single institute study of FLT3 mutation in acute myeloid leukemia with near tetraploidy in Serbia.
Institute of Hematology, Medical School, 11000 Belgrade, Serbia. Journal of Genetics
(Impact Factor: 1.09).
09/2009; 88(2):149-52. DOI: 10.1007/s12041-009-0022-1
Patients with de novo acute myeloid leukemia (AML) and near-tetraploid or completely tetraploid karyotype at presentation are rare. We present four patients with near-tetraploidy/tetraploidy in a cohort of 426 consecutive AML patients (0.98%) in respect to their cytogenetic findings, immunophenotype pattern, response to chemotherapy, course of disease and molecular analyses including tyrosine kinase receptor FLT3 gene, NRAS gene, and tumour suppressor gene, p53. We have found FLT3/ITD mutation only in one patient among the four with near-tetraploidy. The main finding is that these patients had a variable clinical course, with two having a long period of remission (36 and 12 months) and two died, not having achieved remission.
Available from: PubMed Central
Annals of Laboratory Medicine 09/2013; 33(5):371-4. DOI:10.3343/alm.2013.33.5.371 · 1.48 Impact Factor
Available from: Sudha s murthy
[Show abstract] [Hide abstract]
ABSTRACT: Acute myeloid leukemia (AML) is a heterogeneous disorder characterized by specific morphology, immunophenotype and genetic rearrangements. Multiple recurrent chromosomal aberrations have been identified by conventional cytogenetic analysis, which are now widely recognized as one of the most important diagnostic and prognostic determinants in AML. Here, we present a case with unusual cytogenetics, which has been described in very few patients.
Journal of cancer research and therapeutics 04/2014; 10(1):187-90. DOI:10.4103/0973-1482.131406 · 0.79 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.